Use of dried blood spots to measure methotrexate levels and its polyglutamates as biomarkers of methotrexate use in paediatric patients with Juvenile Idiopathic Arthritis (JIA) and Juvenile Dermatomyositis (JDM)

Use of dried blood spots to measure methotrexate levels and its polyglutamates as biomarkers of methotrexate use in paediatric patients with Juvenile Idiopathic Arthritis (JIA) and Juvenile Dermatomyositis (JDM): an observational study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN93945409

Enrollment

Registered

2011-12-02

Start date

2011-04-01

Completion date

Unknown

Last updated

2016-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Juvenile Idiopathic Arthritis (JIA), Juvenile Dermatomyositis (JDM) Musculoskeletal Diseases Juvenile dermatomyositis

Interventions

We will test the possibility of developing an analytical method for the determination of methotrexate and its polyglutamate metabolites in dried blood spot samples. We will also be examining the pract

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Children aged 4-16 years diagnosed with either juvenile idiopathic arthritis or juvenile dermatomyositis (confirmed by a consultant) attending the rheumatology clinic at the paediatric rheumatology outpatient clinics at three sites: the Royal Liverpool Children's Hospital (Liverpool), Musgrave Park Hospital (Belfast) and the University College London (UCL) Institute of Child Health / Great Ormond Street Hospital for Children (GOSH) (London) 2. The child is prescribed methotrexate for at least 2 months (oral or subcutaneous)

Exclusion criteria

Exclusion criteria: Do not meet the above inclusion criteria or if patients (or their parents/ guardians) do not wish to particpate in the research

Design outcomes

Primary

Measure	Time frame
To determine the possibility of developing an analytical method for the determination of methotrexate and its polyglutamate metabolites in dried blood spot samples	—

Secondary

Measure	Time frame
To determine whether home sampling is practical	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 15, 2026